Abstract O O O O
BACKGROUND O O O O
The O O O O
live-attenuated O O O O
yellow O O O O
fever O O O O
vaccine O O O O
(YFV) O O O O
is O O O O
generally O O O O
contraindicated O O O O
in O O O O
immunosuppressed O O O O
patients. O O O O
Our Reason 5 O O
aim Reason 5 O O
was Reason 5 O O
to Reason 5 O O
investigate Reason 5 O O
if Reason 5 O O
immunosuppressive Reason 5 O O
therapy Reason 5 O O
impairs Reason 5 O O
the Reason 5 O O
long-term Reason 5 O O
protection Reason 5 O O
against Reason 5 O O
yellow Reason 5 O O
fever Reason 5 O O
virus Reason 5 O O
in Reason 5 O O
patients Reason 5 O O
who Reason 5 O O
had Reason 5 O O
received Reason 5 O O
YFV Reason 5 O O
prior Reason 5 O O
to Reason 5 O O
the Reason 5 O O
start Reason 5 O O
of Reason 5 O O
their Reason 5 O O
immunosuppressive Reason 5 O O
therapy. Reason 5 O O
METHODS O O O O
Our O O O O
study O O O O
examined O O O O
35 O O O O
healthy O O O O
individuals O O O O
and O O O O
40 O O O O
immunosuppressed O O O O
patients O O O O
with O O O O
autoimmune O O O O
diseases O O O O
or O O O O
organ O O O O
transplants. O O O O
All O O O O
individuals O O O O
had O O O O
received O O O O
YFV O O O O
prior O O O O
to O O O O
the O O O O
onset O O O O
of O O O O
their O O O O
immunosuppression. O O O O
We Reason 4 O O
analysed Reason 4 O O
the Reason 4 O O
long-term Reason 4 O O
influence Reason 4 O O
of Reason 4 O O
the Reason 4 O O
immunosuppressive Reason 4 O O
therapy Reason 4 O O
on Reason 4 O O
the Reason 4 O O
YFV Reason 4 O O
protective Reason 4 O O
immunity Reason 4 O O
by Reason 4 O O
measuring Reason 4 O O
neutralising Reason 4 O O
antibodies Reason 4 O O
(NA) Reason 4 O O
with Reason 4 O O
the Reason 4 O O
Plaque Reason 4 O O
Reduction Reason 4 O O
Neutralisation Reason 4 O O
Test Reason 4 O O
(PRNT). Reason 4 O O
We O O O O
assessed O O O O
risk O O O O
factors O O O O
for O O O O
a O O O O
negative O O O O
PRNT O O O O
result O O O O
(titre O O O O
below O O O O
1: O O O O
10) O O O O
and O O O O
their O O O O
influence O O O O
on O O O O
the O O O O
magnitude O O O O
of O O O O
the O O O O
NA. O O O O
RESULTS Reason 2 O O
A Reason 2 O O
median Reason 2 O O
time Reason 2 O O
interval Reason 2 O O
of Reason 2 O O
21.1 Reason 2 O O
years Reason 2 O O
(interquartile Reason 2 O O
range Reason 2 O O
14.4-31.3 Reason 2 O O
years) Reason 2 O O
after Reason 2 O O
the Reason 2 O O
YFV Reason 2 O O
in Reason 2 O O
all Reason 2 O O
patients, Reason 2 O O
a Reason 2 O O
total Reason 2 O O
of Reason 2 O O
35 Reason 2 O O
immunosuppressed Reason 2 O O
patients Reason 2 O O
(88%) Reason 2 O O
were Reason 2 O O
seropositive Reason 2 O O
(PRNT Reason 2 O O
1:10) Reason 2 O O
compared Reason 2 O O
to Reason 2 O O
31 Reason 2 O O
patients Reason 2 O O
(89%) Reason 2 O O
in Reason 2 O O
the Reason 2 O O
control Reason 2 O O
group. Reason 2 O O
The Reason 2 O O
geometric Reason 2 O O
mean Reason 2 O O
titres Reason 2 O O
of Reason 2 O O
NA Reason 2 O O
did Reason 2 O O
not Reason 2 O O
differ Reason 2 O O
between Reason 2 O O
the Reason 2 O O
groups. Reason 2 O O
The Reason 2 O O
duration Reason 2 O O
of Reason 2 O O
an Reason 2 O O
underlying Reason 2 O O
rheumatic Reason 2 O O
disease Reason 2 O O
was Reason 2 O O
the Reason 2 O O
only Reason 2 O O
risk Reason 2 O O
factor Reason 2 O O
found Reason 2 O O
for Reason 2 O O
a Reason 2 O O
lower Reason 2 O O
magnitude Reason 2 O O
of Reason 2 O O
NA. Reason 2 O O
An Reason 2 O O
insufficient Reason 2 O O
level Reason 2 O O
of Reason 2 O O
NA Reason 2 O O
was Reason 2 O O
found Reason 2 O O
in Reason 2 O O
nine Reason 2 O O
subjects Reason 2 O O
(12%) Reason 2 O O
who Reason 2 O O
had Reason 2 O O
received Reason 2 O O
a Reason 2 O O
single Reason 2 O O
dose Reason 2 O O
of Reason 2 O O
YFV Reason 2 O O
(in Reason 2 O O
one Reason 2 O O
subject, Reason 2 O O
the Reason 2 O O
number Reason 2 O O
of Reason 2 O O
YFV Reason 2 O O
doses Reason 2 O O
was Reason 2 O O
unknown). Reason 2 O O
CONCLUSION Reason 5 O O
The Reason 5 O O
use Reason 5 O O
of Reason 5 O O
an Reason 5 O O
immunosuppressive Reason 5 O O
drug Reason 5 O O
started Reason 5 O O
after Reason 5 O O
the Reason 5 O O
administration Reason 5 O O
of Reason 5 O O
the Reason 5 O O
YFV Reason 5 O O
did Reason 5 O O
not Reason 5 O O
affect Reason 5 O O
long-term Reason 5 O O
persistence Reason 5 O O
of Reason 5 O O
NA. Reason 5 O O
A Reason 5 O O
second Reason 5 O O
dose Reason 5 O O
of Reason 5 O O
YFV Reason 5 O O
may Reason 5 O O
be Reason 5 O O
necessary Reason 5 O O
to Reason 5 O O
secure Reason 5 O O
long-term Reason 5 O O
immunity. Reason 5 O O
